AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00600470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor-office collaborative care (DOCC) management
Description: DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
Study NCT00600470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU involves routine care: psychoeducation and referral to outside providers.
Study NCT05261308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: new prosthesis
Description: Operation to fix the new prosthesis
Study NCT03306420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4112
Description: All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Study NCT03346005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aeonose
Description: An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
Study NCT02204657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System
Description: Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
Study NCT00757627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: etoricoxib 60 mg QD for 4 weeks.
Study NCT00858689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
Study NCT01343758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose in normal saline
Description: Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
Study NCT02867917 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Volcolon sugar free
Description: 1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
Study NCT02867917 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metamucil Orange
Description: 1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
Study NCT02867917 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Psyllium Orange
Description: 1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
Study NCT02471989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Study NCT02471989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GERD diet
Study NCT00798291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ad lib diet and Control placebo
Description: one packet with water two times a day
Study NCT00798291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad lib diet and An 777
Description: one packet with water two times a day
Study NCT00798291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad lib diet/ placebo/ exercise
Description: one packet with water two times a day; resistance training three times a week
Study NCT00798291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad lib diet; AN 777; exercise
Description: one packet with water two times a day; resistance training three times a week
Study NCT04118881 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ear Acupuncture
Description: Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
Study NCT04118881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear Acupuncture
Description: Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
Study NCT02700659 — intervention group
Intervention type: OTHER
Intervention: Cxbladder
Description: Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
Study NCT03624153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic-assisted intervention
Description: Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
Study NCT03624153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation intervention
Description: Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
Study NCT02202785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 IV infusion
Study NCT01294436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral Dose 5 or 10 mg
Study NCT01987362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
Study NCT04356534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma therapy using convalescent plasma with antibody against SARS-CoV-2
Description: convalescent patient plasma plus routine local standard of care
Study NCT04356534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care for COVID-19 patients
Description: local standard of care which include antivirals and supportive care
Study NCT04743531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROs
Description: Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.
Study NCT01754753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Friendship groups
Study NCT00208325 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P.F.C Sigma Fixed Bearing total knee system
Description: Orthopaedic implant for total knee replacement
Study NCT00208325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C Sigma RP Mobile Bearing knee system
Description: Orthopaedic implant for total knee replacement
Study NCT01701336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut, MVA-NSmut
Description: 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
Study NCT01766713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg daily oral dose of ezetimibe
Study NCT01766713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: 10mg daily oral dose of ezetimibe
Study NCT02119247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHF 6001 dry powder for inhalation via NEXThaler®
Study NCT02119247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CHF 6001 DPI capsules for inhalation via Aerolizer
Study NCT01774045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421
Study NCT01774045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00108745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Undergo observation
Study NCT00108745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00108745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00108745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00108745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00108745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Given IV
Study NCT00108745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00108745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00108745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00243074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00243074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00106301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK228 (romidepsin)
Description: Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study NCT04444934 — intervention group
Intervention type: OTHER
Intervention: histological examination
Description: Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
Study NCT03525470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Water
Description: 150 mil of water was drunk on two occasions
Study NCT03525470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No drink
Description: Although body weight lost no drink consumed
Study NCT00921947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX102
Description: Universal M2e influenza vaccine
Study NCT01739023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Schwann Cells
Description: Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
Study NCT00542204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online disease management
Description: The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
Study NCT00664534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
Study NCT00664534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Premix (mid-mixture and low-mixture)
Description: patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
Study NCT00600613 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: cone beam imaging
Description: All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
Study NCT04797234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: There will be no intervention to the control group.
Study NCT04797234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment
Description: The experimental group will be trained for 6 weeks.
Study NCT03003585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
Study NCT03003585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
Study NCT03242343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Description: An external support device for AV fistula
Study NCT04494204 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Immunofree tablets and Reginmune capsule
Description: 2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
Study NCT04494204 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Immunofree tablets and Reginmune capsule
Description: 2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
Study NCT00618579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
Study NCT00618579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
Study NCT00618579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
Study NCT02336425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 120 mg per 1 mL liquid in vial
Study NCT02336425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 0 mg per 1 mL liquid in vial
Study NCT03749135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: anti-IL4-Receptor alpha
Study NCT03749135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04051086 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Physical examination and Urine and blood samples
Description: Only one visit for each participant : A large majority of visits will be part of patients' usual care~* Medical examination : birth, weight, gender, blood pressure, medical history~* Urine and blood samples
Study NCT04051086 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Urine and blood samples
Description: Only one visit for each participant~* Medical history~* Urine and blood samples
Study NCT02338063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
Study NCT02338063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: 4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
Study NCT01608295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone; Viibryd
Description: Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
Study NCT01608295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine; Paxil
Description: Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
Study NCT02331537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavior therapy
Description: Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
Study NCT02324972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Synthetic SHIP1 activator
Study NCT02324972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03262181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: 5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
Study NCT03262181 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation
Description: 5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
Study NCT05762809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Y-balance test
Description: The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
Study NCT05762809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements
Description: Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
Study NCT00135707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement/Vitamins
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.